Affinofile Profiling: How Efficiency of CD4/CCR5 Usage Impacts the Biological and Pathogenic Phenotype of HIV

Overview

Journal Virology

Specialty Microbiology

Date 2012 Dec 11

PMID 23217618

Citations 15

Authors

Kelechi Chikere

Tom Chou

Paul R Gorry

Benhur Lee

Affiliations

Soon will be listed here.

Abstract

HIV-1 envelope (Env) uses CD4 and a coreceptor (CCR5 and/or CXCR4) for viral entry. The efficiency of receptor/coreceptor mediated entry has important implications for HIV pathogenesis and transmission. The advent of CCR5 inhibitors in clinical use also underscores the need for quantitative and predictive tools that can guide therapeutic management. Historically, measuring the efficiency of CD4/CCR5 mediated HIV entry has relied on surrogate and relatively slow throughput assays that cannot adequately capture the full spectrum of Env phenotypes. In this review, we discuss the details of the Affinofile receptor affinity profiling system that has provided a quantitative and higher throughput method to characterize viral entry efficiency as a function of CD4 and CCR5 expression levels. We will then review how the Affinofile system has been used to reveal the distinct pathophysiological properties associated with Env entry phenotypes and discuss potential shortcomings of the current system.

Citing Articles

Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env.

Schapiro H, Khasnis M, Ahn K, Karagiaridi A, Hayden S, Cilento M PLoS Pathog. 2022; 18(5):e1010531.

PMID: 35584191 PMC: 9154124. DOI: 10.1371/journal.ppat.1010531.

Modular Lentiviral Vectors for Highly Efficient Transgene Expression in Resting Immune Cells.

Fichter C, Aggarwal A, Wong A, McAllery S, Mathivanan V, Hao B Viruses. 2021; 13(6).

PMID: 34207354 PMC: 8235771. DOI: 10.3390/v13061170.

Roles of phosphatidylserine exposed on the viral envelope and cell membrane in HIV-1 replication.

Chua B, Ngo J, Situ K, Morizono K Cell Commun Signal. 2019; 17(1):132.

PMID: 31638994 PMC: 6805584. DOI: 10.1186/s12964-019-0452-1.

The Effects of Statistical Multiplicity of Infection on Virus Quantification and Infectivity Assays.

Mistry B, DOrsogna M, Chou T Biophys J. 2018; 114(12):2974-2985.

PMID: 29925033 PMC: 6026352. DOI: 10.1016/j.bpj.2018.05.005.

Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.

Beauparlant D, Rusert P, Magnus C, Kadelka C, Weber J, Uhr T PLoS Pathog. 2017; 13(3):e1006255.

PMID: 28264054 PMC: 5354460. DOI: 10.1371/journal.ppat.1006255.

References

Kimata J, Gosink J, Kewalramani V, Rudensey L, Littman D, Overbaugh J . Coreceptor specificity of temporal variants of simian immunodeficiency virus Mne. J Virol. 1999; 73(2):1655-60. PMC: 103994. DOI: 10.1128/JVI.73.2.1655-1660.1999. View

Gorry P, Taylor J, Holm G, Mehle A, Morgan T, Cayabyab M . Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol. 2002; 76(12):6277-92. PMC: 136234. DOI: 10.1128/jvi.76.12.6277-6292.2002. View

PLATT E, Wehrly K, Kuhmann S, Chesebro B, Kabat D . Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol. 1998; 72(4):2855-64. PMC: 109730. DOI: 10.1128/JVI.72.4.2855-2864.1998. View

Tilton J, Wilen C, Didigu C, Sinha R, Harrison J, Agrawal-Gamse C . A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol. 2010; 84(20):10863-76. PMC: 2950574. DOI: 10.1128/JVI.01109-10. View

Westby M . Resistance to CCR5 antagonists. Curr Opin HIV AIDS. 2009; 2(2):137-44. DOI: 10.1097/COH.0b013e3280142007. View

Roche M, Jakobsen M, Sterjovski J, Ellett A, Posta F, Lee B . HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J Virol. 2011; 85(9):4330-42. PMC: 3126252. DOI: 10.1128/JVI.00106-11. View

Gray L, Sterjovski J, Churchill M, Ellery P, Nasr N, Lewin S . Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology. 2005; 337(2):384-98. DOI: 10.1016/j.virol.2005.04.034. View

Sato S, Ouellet M, St-Pierre C, Tremblay M . Glycans, galectins, and HIV-1 infection. Ann N Y Acad Sci. 2012; 1253:133-48. DOI: 10.1111/j.1749-6632.2012.06475.x. View

Dejucq N, Simmons G, Clapham P . Expanded tropism of primary human immunodeficiency virus type 1 R5 strains to CD4(+) T-cell lines determined by the capacity to exploit low concentrations of CCR5. J Virol. 1999; 73(9):7842-7. PMC: 104314. DOI: 10.1128/JVI.73.9.7842-7847.1999. View

10.

Trkola A, Dragic T, Arthos J, Binley J, Olson W, Allaway G . CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 1996; 384(6605):184-7. DOI: 10.1038/384184a0. View

11.

Clapham P, Blanc D, Weiss R . Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency virus. Virology. 1991; 181(2):703-15. PMC: 7131431. DOI: 10.1016/0042-6822(91)90904-p. View

12.

Zolla-Pazner S, Cardozo T . Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol. 2010; 10(7):527-35. PMC: 3167078. DOI: 10.1038/nri2801. View

13.

Kikukawa R, Koyanagi Y, Harada S, Kobayashi N, Hatanaka M, Yamamoto N . Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4. J Virol. 1986; 57(3):1159-62. PMC: 252852. DOI: 10.1128/JVI.57.3.1159-1162.1986. View

14.

Chesebro B, Buller R, Portis J, Wehrly K . Failure of human immunodeficiency virus entry and infection in CD4-positive human brain and skin cells. J Virol. 1990; 64(1):215-21. PMC: 249089. DOI: 10.1128/JVI.64.1.215-221.1990. View

15.

Pakarasang M, Wasi C, Suwanagool S, Chalermchockcharoenkit A, Auewarakul P . Increased HIV-DNA load in CCR5-negative lymphocytes without viral phenotypic change. Virology. 2006; 347(2):372-8. DOI: 10.1016/j.virol.2005.12.003. View

16.

Dalgleish A, Beverley P, Clapham P, Crawford D, Greaves M, Weiss R . The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984; 312(5996):763-7. DOI: 10.1038/312763a0. View

17.

Nedellec R, Coetzer M, Shimizu N, Hoshino H, Polonis V, Morris L . Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype. J Virol. 2009; 83(17):8353-63. PMC: 2738165. DOI: 10.1128/JVI.00780-09. View

18.

Rangel H, Weber J, Chakraborty B, Gutierrez A, Marotta M, Mirza M . Role of the human immunodeficiency virus type 1 envelope gene in viral fitness. J Virol. 2003; 77(16):9069-73. PMC: 167250. DOI: 10.1128/jvi.77.16.9069-9073.2003. View

19.

Lin N, Kuritzkes D . Tropism testing in the clinical management of HIV-1 infection. Curr Opin HIV AIDS. 2010; 4(6):481-7. PMC: 2874683. DOI: 10.1097/COH.0b013e328331b929. View

20.

Smit T, Wang B, Ng T, Osborne R, Brew B, Saksena N . Varied tropism of HIV-1 isolates derived from different regions of adult brain cortex discriminate between patients with and without AIDS dementia complex (ADC): evidence for neurotropic HIV variants. Virology. 2001; 279(2):509-26. DOI: 10.1006/viro.2000.0681. View